Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

NASDAQ:JANX

Overview | Financials
Company Name Janux Therapeutics, Inc.
Symbol JANX
Currency USD
Price 41.26
Market Cap 2,152,307,270
Dividend Yield 0%
52-week-range 5.65 - 65.6
Industry Biotechnology
Sector Healthcare
CEO Dr. David Alan Campbell Ph.D.
Website https://www.januxrx.com

An error occurred while fetching data.

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface

Related Stocks

OptimizeRx Corporation logo

OptimizeRx Corporation

OPRX

7.54 USD

Seer, Inc. logo

Seer, Inc.

SEER

1.64 USD

Ocugen, Inc. logo

Ocugen, Inc.

OCGN

1.14 USD

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

3.6 USD

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

3.79 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

3.29 USD

Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

23.33 USD

Financials

Numbers are in millions USD

Numbers are in millions USD